---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000078"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:46:04.674196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Keros completes Phase 2 PAH trial TROPOS enrollment with 113 patients; topline Q2 2025

## Summary
- Completed enrollment of TROPOS Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
- Enrolled 113 patients, exceeding the initial target of 90 patients.
- Topline data expected to be presented in the second quarter of 2025.
- Trial evaluates cibotercept in combination with background therapy.

## SEC filing metadata
- accession: 0001664710-24-000078
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000078/0001664710-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000078/kros-20240930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000078
- JSON: https://secwatch.observer/filing/0001664710-24-000078.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.